The Bcl-2-inhibitor venetoclax and the c-IAP1/c-IAP2 inhibitor BV6 can enhance TMZ toxicity at early times after TMZ treatment and, most importantly, also target senescent glioblastoma cells at later times. This evidence concerns the gene BCL2 and glioblastoma.